Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas

E. Sala, P. Bellaviti Buttoni, E. Malchiodi, E. Verrua, G. Carosi, E. Profka, G. Rodari, M. Filopanti, E. Ferrante, A. Spada, G. Mantovani

Research output: Contribution to journalArticle

Abstract

Background: The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction. Materials: We analyzed 74 patients (mean age = 46.9 ± 14.4, M/F = 19/55, macro/micro = 18/56) bearing a prolactinoma divided in 3 groups: group A (23) treated for 3 years, group B (23) for a period between 3 and 5 years, and group C (28) for a period >5 years. CAB therapy was interrupted according to Endocrine Society Guidelines. Prolactin (PRL) levels were measured 3, 6, 12 and 24 months after withdrawal. Recurrence was defined with PRL levels ≥30 ng/ml. Results: Groups did not differ in pretreatment PRL levels (123.2 ± 112.1, 120.9 ± 123.8, 176.6 ± 154.0), pituitary deficit (4, 17, 17 %), mean CAB weekly dose (0.7 ± 0.4, 0.6 ± 0.3, 0.7 ± 0.4) and PRL levels before withdrawal (17.1 ± 19.6, 11.4 ± 8.8, 13.8 ± 13.5). Recurrence occurred within 12 months in 34 patients (45.9 %), without significant differences among groups. Neuroradiological evaluation showed a significantly higher presence of macroadenoma in group C (13, 17 and 39 %, respectively). Recurrence rate of hyperprolactinemia did not depend on sex, tumor size or CAB dose but it was significantly correlated with PRL levels at diagnosis and before withdrawal (p = 0.03). Finally, patients with pituitary deficit at diagnosis showed a significantly higher recurrence rate (p = 0.03). Conclusions: The study provides additional evidence that prolonging therapy for more than 3 years does not reduce recurrence rate. In particular, recurrence risk was similar in micro- and macroadenomas, and higher in patients with pituitary deficits at diagnosis.

Original languageEnglish
Pages (from-to)1377-1382
Number of pages6
JournalJournal of Endocrinological Investigation
Volume39
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Prolactinoma
Hyperprolactinemia
Dopamine Agonists
Prolactin
Recurrence
Guidelines
Neoplasms
Therapeutics
cabergoline

Keywords

  • Dopamine agonist therapy
  • Hyperprolactinemia
  • Pituitary adenoma
  • Prolactinomas
  • Recurrence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. / Sala, E.; Bellaviti Buttoni, P.; Malchiodi, E.; Verrua, E.; Carosi, G.; Profka, E.; Rodari, G.; Filopanti, M.; Ferrante, E.; Spada, A.; Mantovani, G.

In: Journal of Endocrinological Investigation, Vol. 39, No. 12, 01.12.2016, p. 1377-1382.

Research output: Contribution to journalArticle

Sala, E, Bellaviti Buttoni, P, Malchiodi, E, Verrua, E, Carosi, G, Profka, E, Rodari, G, Filopanti, M, Ferrante, E, Spada, A & Mantovani, G 2016, 'Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas', Journal of Endocrinological Investigation, vol. 39, no. 12, pp. 1377-1382. https://doi.org/10.1007/s40618-016-0483-z
Sala, E. ; Bellaviti Buttoni, P. ; Malchiodi, E. ; Verrua, E. ; Carosi, G. ; Profka, E. ; Rodari, G. ; Filopanti, M. ; Ferrante, E. ; Spada, A. ; Mantovani, G. / Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. In: Journal of Endocrinological Investigation. 2016 ; Vol. 39, No. 12. pp. 1377-1382.
@article{00deb1d8ccb44eba8f7792bd0f52304e,
title = "Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas",
abstract = "Background: The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction. Materials: We analyzed 74 patients (mean age = 46.9 ± 14.4, M/F = 19/55, macro/micro = 18/56) bearing a prolactinoma divided in 3 groups: group A (23) treated for 3 years, group B (23) for a period between 3 and 5 years, and group C (28) for a period >5 years. CAB therapy was interrupted according to Endocrine Society Guidelines. Prolactin (PRL) levels were measured 3, 6, 12 and 24 months after withdrawal. Recurrence was defined with PRL levels ≥30 ng/ml. Results: Groups did not differ in pretreatment PRL levels (123.2 ± 112.1, 120.9 ± 123.8, 176.6 ± 154.0), pituitary deficit (4, 17, 17 {\%}), mean CAB weekly dose (0.7 ± 0.4, 0.6 ± 0.3, 0.7 ± 0.4) and PRL levels before withdrawal (17.1 ± 19.6, 11.4 ± 8.8, 13.8 ± 13.5). Recurrence occurred within 12 months in 34 patients (45.9 {\%}), without significant differences among groups. Neuroradiological evaluation showed a significantly higher presence of macroadenoma in group C (13, 17 and 39 {\%}, respectively). Recurrence rate of hyperprolactinemia did not depend on sex, tumor size or CAB dose but it was significantly correlated with PRL levels at diagnosis and before withdrawal (p = 0.03). Finally, patients with pituitary deficit at diagnosis showed a significantly higher recurrence rate (p = 0.03). Conclusions: The study provides additional evidence that prolonging therapy for more than 3 years does not reduce recurrence rate. In particular, recurrence risk was similar in micro- and macroadenomas, and higher in patients with pituitary deficits at diagnosis.",
keywords = "Dopamine agonist therapy, Hyperprolactinemia, Pituitary adenoma, Prolactinomas, Recurrence",
author = "E. Sala and {Bellaviti Buttoni}, P. and E. Malchiodi and E. Verrua and G. Carosi and E. Profka and G. Rodari and M. Filopanti and E. Ferrante and A. Spada and G. Mantovani",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40618-016-0483-z",
language = "English",
volume = "39",
pages = "1377--1382",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "12",

}

TY - JOUR

T1 - Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas

AU - Sala, E.

AU - Bellaviti Buttoni, P.

AU - Malchiodi, E.

AU - Verrua, E.

AU - Carosi, G.

AU - Profka, E.

AU - Rodari, G.

AU - Filopanti, M.

AU - Ferrante, E.

AU - Spada, A.

AU - Mantovani, G.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction. Materials: We analyzed 74 patients (mean age = 46.9 ± 14.4, M/F = 19/55, macro/micro = 18/56) bearing a prolactinoma divided in 3 groups: group A (23) treated for 3 years, group B (23) for a period between 3 and 5 years, and group C (28) for a period >5 years. CAB therapy was interrupted according to Endocrine Society Guidelines. Prolactin (PRL) levels were measured 3, 6, 12 and 24 months after withdrawal. Recurrence was defined with PRL levels ≥30 ng/ml. Results: Groups did not differ in pretreatment PRL levels (123.2 ± 112.1, 120.9 ± 123.8, 176.6 ± 154.0), pituitary deficit (4, 17, 17 %), mean CAB weekly dose (0.7 ± 0.4, 0.6 ± 0.3, 0.7 ± 0.4) and PRL levels before withdrawal (17.1 ± 19.6, 11.4 ± 8.8, 13.8 ± 13.5). Recurrence occurred within 12 months in 34 patients (45.9 %), without significant differences among groups. Neuroradiological evaluation showed a significantly higher presence of macroadenoma in group C (13, 17 and 39 %, respectively). Recurrence rate of hyperprolactinemia did not depend on sex, tumor size or CAB dose but it was significantly correlated with PRL levels at diagnosis and before withdrawal (p = 0.03). Finally, patients with pituitary deficit at diagnosis showed a significantly higher recurrence rate (p = 0.03). Conclusions: The study provides additional evidence that prolonging therapy for more than 3 years does not reduce recurrence rate. In particular, recurrence risk was similar in micro- and macroadenomas, and higher in patients with pituitary deficits at diagnosis.

AB - Background: The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction. Materials: We analyzed 74 patients (mean age = 46.9 ± 14.4, M/F = 19/55, macro/micro = 18/56) bearing a prolactinoma divided in 3 groups: group A (23) treated for 3 years, group B (23) for a period between 3 and 5 years, and group C (28) for a period >5 years. CAB therapy was interrupted according to Endocrine Society Guidelines. Prolactin (PRL) levels were measured 3, 6, 12 and 24 months after withdrawal. Recurrence was defined with PRL levels ≥30 ng/ml. Results: Groups did not differ in pretreatment PRL levels (123.2 ± 112.1, 120.9 ± 123.8, 176.6 ± 154.0), pituitary deficit (4, 17, 17 %), mean CAB weekly dose (0.7 ± 0.4, 0.6 ± 0.3, 0.7 ± 0.4) and PRL levels before withdrawal (17.1 ± 19.6, 11.4 ± 8.8, 13.8 ± 13.5). Recurrence occurred within 12 months in 34 patients (45.9 %), without significant differences among groups. Neuroradiological evaluation showed a significantly higher presence of macroadenoma in group C (13, 17 and 39 %, respectively). Recurrence rate of hyperprolactinemia did not depend on sex, tumor size or CAB dose but it was significantly correlated with PRL levels at diagnosis and before withdrawal (p = 0.03). Finally, patients with pituitary deficit at diagnosis showed a significantly higher recurrence rate (p = 0.03). Conclusions: The study provides additional evidence that prolonging therapy for more than 3 years does not reduce recurrence rate. In particular, recurrence risk was similar in micro- and macroadenomas, and higher in patients with pituitary deficits at diagnosis.

KW - Dopamine agonist therapy

KW - Hyperprolactinemia

KW - Pituitary adenoma

KW - Prolactinomas

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84994908978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994908978&partnerID=8YFLogxK

U2 - 10.1007/s40618-016-0483-z

DO - 10.1007/s40618-016-0483-z

M3 - Article

AN - SCOPUS:84994908978

VL - 39

SP - 1377

EP - 1382

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 12

ER -